Short Interest in Apyx Medical Co. (NASDAQ:APYX) Declines By 39.0%

Apyx Medical Co. (NASDAQ:APYX) saw a large decrease in short interest during the month of November. As of November 15th, there was short interest totalling 140,500 shares, a decrease of 39.0% from the October 31st total of 230,300 shares. Based on an average daily trading volume, of 42,400 shares, the days-to-cover ratio is presently 3.3 days. Currently, 0.5% of the company’s shares are sold short.

Apyx Medical Stock Up 16.6 %

APYX stock opened at $1.69 on Thursday. Apyx Medical has a fifty-two week low of $0.97 and a fifty-two week high of $3.26. The company has a market capitalization of $63.61 million, a price-to-earnings ratio of -1.94 and a beta of 1.21. The business’s 50 day moving average price is $1.24 and its two-hundred day moving average price is $1.32. The company has a debt-to-equity ratio of 3.03, a quick ratio of 4.52 and a current ratio of 5.46.

Apyx Medical (NASDAQ:APYX) last announced its quarterly earnings data on Friday, November 8th. The company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.15) by $0.01. Apyx Medical had a negative return on equity of 137.98% and a negative net margin of 58.59%. The business had revenue of $11.49 million during the quarter, compared to analyst estimates of $11.66 million. During the same quarter last year, the firm posted ($0.13) earnings per share. As a group, analysts forecast that Apyx Medical will post -0.68 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms have weighed in on APYX. BTIG Research initiated coverage on Apyx Medical in a research report on Thursday, October 17th. They issued a “neutral” rating on the stock. Craig Hallum upgraded shares of Apyx Medical to a “strong-buy” rating in a report on Thursday, October 24th. Finally, JMP Securities restated a “market perform” rating on shares of Apyx Medical in a report on Monday, September 16th.

Hedge Funds Weigh In On Apyx Medical

A number of hedge funds have recently bought and sold shares of APYX. RPg Family Wealth Advisory LLC bought a new stake in shares of Apyx Medical in the 2nd quarter worth $101,000. Rathbones Group PLC boosted its holdings in shares of Apyx Medical by 148.0% during the 2nd quarter. Rathbones Group PLC now owns 251,334 shares of the company’s stock valued at $337,000 after acquiring an additional 150,000 shares during the last quarter. Private Advisor Group LLC raised its holdings in shares of Apyx Medical by 3.9% during the third quarter. Private Advisor Group LLC now owns 322,321 shares of the company’s stock valued at $400,000 after purchasing an additional 12,180 shares during the last quarter. Commonwealth Equity Services LLC lifted its position in Apyx Medical by 2.9% during the second quarter. Commonwealth Equity Services LLC now owns 511,561 shares of the company’s stock valued at $685,000 after purchasing an additional 14,481 shares during the period. Finally, Royce & Associates LP boosted its holdings in Apyx Medical by 3.4% in the third quarter. Royce & Associates LP now owns 2,582,490 shares of the company’s stock worth $3,202,000 after purchasing an additional 85,267 shares during the last quarter. Institutional investors own 55.33% of the company’s stock.

Apyx Medical Company Profile

Apyx Medical Corporation, an energy technology company, engages in the design, development, and manufacture of medical devices in the United States and internationally. The company operates through two segments: Advanced Energy and Original Equipment Manufacturing (OEM). It offers Helium Plasma Generator for delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures.